Startup · $13m raised
Every investor coverage indicates participated in a round Okogen raised.
| Investor | Rounds | Invested |
|---|---|---|
| Brandon Capital | Series A | $13,000,000 |
| Medical Research Commercialisation Fund (MRCF) | Series A | - |
Companies Okogen acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Brian M. Strem | Chief Executive Officer | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
Stories naming Okogen. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Okogen has begun Australian Phase II trials of its conjunctivitis therapy OKG-0301 across multiple sites, with Brandon Capital's MRCF having invested in the biotech's Series A in December 2017.